NCT06468267View on ClinicalTrials.gov

RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

July 15, 2026

Study Completion Date

July 15, 2026

Conditions

Peripheral T Cell Lymphoma

Interventions

DRUG

Thiotepa

The reduced intensity conditioning regimen is composed by thiotepa (5mg / kg / d-7d (1d)), fludarabine (30mg / m2 / d, -6d--2d (5d)), Ara-C (1g / m2 / d, -6d--2d (5d)), and busulfan (3.2mg / kg / d, -4d-3d (2d)).

Trial Locations (1)

200080

RECRUITING

Shanghai General Hospital, Shanghai

All Listed Sponsors

lead

Xianmin Song, MD

OTHER